Core Insights - The company announced a cash dividend of 10 yuan per 10 shares, totaling 78.3072 million yuan, which represents 59.32% of the net profit attributable to shareholders for the first half of 2025 [1] - Since its IPO in 2021, the company has distributed a total of 1.28 billion yuan in cash dividends, which is approximately 70% of the funds raised during the IPO, reflecting its commitment to shareholder returns [1] - The company has implemented two share buyback programs, repurchasing 2.066 million shares, accounting for 2.61% of the total share capital, with a total investment exceeding 175 million yuan [1] Financial Performance - In the first half of 2025, the company achieved a revenue of 430 million yuan, representing a year-on-year growth of 8.41% [2] - The net profit attributable to shareholders for the same period was 132 million yuan, showing a year-on-year increase of 6.57% [2] R&D and Market Strategy - The company invested 48.1957 million yuan in R&D in the first half of 2025, which is 11.21% of its sales [2] - During the reporting period, the company launched 140 new products and obtained 23 new patents/software copyrights, along with 203 new medical device certifications [2] - The company is focusing on a global strategy, participating in various domestic and international exhibitions to enhance brand influence and market competitiveness, with products exported to over 170 countries and regions [2] Future Plans - The company has developed a "Quality Improvement, Efficiency Enhancement, and Return Focus" action plan for 2025, which includes measures to focus on core operations, advance fundraising project construction, strengthen investor communication, and emphasize shareholder returns [2] - The plan aims to fulfill the responsibilities of a listed company through strong performance, sound corporate governance, and active investor returns, thereby maintaining market image and promoting stable operations in the Sci-Tech Innovation Board [2]

Core Viewpoint - Kefu Medical has submitted a listing application to the Hong Kong Stock Exchange, aiming to raise funds for expanding overseas sales channels, global investments and acquisitions, research and development innovations, and domestic market promotion [1] Group 1: Company Overview - Kefu Medical is a leading enterprise in China's home medical device industry, with over 200 product categories [1] - The company ranks second in sales in China for 2024 [1] - Kefu Medical is actively expanding its online channels, covering all major e-commerce platforms, and is projected to rank second in online sales in the industry for 2024 [1] Group 2: Business Operations - As of June 30, 2025, Kefu Medical operates 738 self-owned stores, with 689 being "Jianer Hearing" service centers, covering 135 cities nationwide [1] - The rehabilitation aids segment is the most significant growth area for revenue, particularly in correction, posture correction products, and hearing aids [1]

Group 1: R&D Investment and Achievements - The company has achieved 41 invention patents and 7 utility model patents as of June 30, 2025, with a focus on innovative products such as eco-friendly elastic glue and digital printing products [2][3] - R&D investment reached CNY 14.92 million in the first half of 2025, representing an 8.58% year-on-year increase [3] Group 2: Cost Control Measures - The company has established a "three-in-one" cost control system focusing on procurement, production, and R&D to optimize production costs [3][4] - **Procurement**: Leveraging bulk purchasing advantages and long-term partnerships with suppliers to reduce raw material costs [3] - **Production**: Utilizing self-developed automated cleaning production technology to enhance efficiency and reduce labor and energy costs [3] - **R&D**: Developing core raw materials in-house to minimize material costs and optimize production processes [4] Group 3: Environmental and Safety Initiatives - The company prioritizes environmental protection and safety in its sustainable development strategy, implementing continuous improvements in production processes [4][5] - Compliance with national policies on pollutant discharge and waste recycling is strictly enforced [5] Group 4: Automation and Customer Service - The establishment of an automated printing laboratory allows for simulation of customer production scenarios, aiding in the provision of tailored solutions [5] Group 5: Supply Chain Management - In response to fluctuations in international oil prices, the company aims to stabilize production and performance by enhancing supply chain management and establishing stable supplier relationships [5]

Group 1: Financial Performance - The company's revenue in the first half of the year decreased by 15.44% compared to the same period last year, primarily due to changes in industry demand and adjustments in procurement prices [2][3] - The company's cash funds decreased by 47.18% since the beginning of the year, attributed to an increase in cash management limits for idle funds, which will not affect normal operations or future investment plans [3][4] - As of June 30, 2025, revenue from the South China region accounted for 45%, while revenue from outside South China accounted for 55% [4] Group 2: Strategic Plans and Market Expansion - The company is open to mergers and acquisitions that can create synergies with existing operations and extend the industrial chain, supported by the establishment of a strategic planning department [3][4] - Future market expansion will focus on enhancing the marketing system and exploring overseas markets to increase overall market share [4][5] - The company plans to deepen its marketing system and focus on new product development to stabilize market size amid declining sales of certain products [7][8] Group 3: Research and Development - R&D expenses decreased year-on-year but accounted for approximately 38% of the company's revenue, reflecting a commitment to research despite the decline [6][7] - The company emphasizes innovation in product development, with new products typically taking 3-5 years from initiation to certification [4][6] - A dynamic review mechanism for ongoing projects will be implemented to adjust R&D efforts based on market dynamics and end-user needs [4][8] Group 4: Competitive Strategy - The company maintains a multi-diagnostic technology platform, focusing on infectious diseases, precision medicine, and public health, to enhance service quality and market competitiveness [5][7] - Challenges in overseas markets include geopolitical policies and competition, with the company primarily serving clients in Latin America and Southeast Asia [6][7] - The company aims to improve operational efficiency through strategic adjustments and cost reduction measures in response to industry policies and market demands [7][8]

了解2025年上海辖区上市公司集体接待日，请点击：https://rs.p5w.net/html/175611728073329.shtml 就新品开发以及推广计划，吴克兢称，公司根据产品储备情况，进行改良性新药的研发；对储备品种开 展二次升级开发；与科研院校开展深度合作，积极开展化学药、中成药、新产品、中药大健康产品的开 发工作，推进研发创新。 谈及海外市场情况，吴克兢介绍，公司的控股孙公司贵州广得利医药用品有限公司，其主要产品为明胶 空心胶囊、植物胶囊（HPMC纤维素空心胶囊、普鲁兰多糖空心胶囊）。2024年起，该公司产品出口到 北美（美国、加拿大）、南美（巴西等）、澳洲、欧洲（西班牙、德国）及东南亚地区。2025年，受关 税因素影响，该公司暂停向美国出口产品。截至2025年半年度实现出口业务收入1,833,947.39元，占公 司营业收入总额的0.19%。除此外，公司暂无海外市场拓展计划。（全景网） 为进一步加强与投资者的互动交流，神奇制药（600613.SH）于9月19日（周五）15:00-17:00参加由上海 上市公司协会与全景网联合举办，主题为"沟通传递价值 信心共筑未来"——2025年上海辖区上 ...

证券代码：300833 证券简称：浩洋股份 广州市浩洋电子股份有限公司 投资者关系活动记录表 编号：2025-004 投资者关系 活动类别 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称 及人员姓名 详见附件 时间 2025年9月18日至2025年9月19日 地点 公司会议室 上 市 公 司 接 待人员姓名 董事会秘书 劳杰伟先生 投资者关系活动 主要内容介绍 交流环节： 公司是一家集舞台娱乐灯光设备、建筑照明设备、桁架设备等产品的研发、生 产与销售为一体的高新技术企业。2025年上半年公司持续加大研发投入，挖掘新的 机遇；整合丹麦SGM公司，提升发展动能；新总部投入使用，优化产能资源。2025 年上半年公司受贸易环境的变化影响，有所承压。2025年半年度公司实现营业收入 约人民币5.22亿元，同比下降约21.99%；实现归属于母公司所有者的净利润约人民 币0.78亿元，同比下降约61.69%。 Q&A： 1. 丹麦子公司最新情况如何？ 公司收购了丹麦SGM公司资产，相继在丹麦和美国成立子公司，整合利用其技 术及产能，其品牌定位为建筑艺术照明及 ...

Core Viewpoint - Dingyang Technology (stock code: 688112.SH) has launched two high-end testing and measurement instruments, showcasing its strong R&D capabilities and strategic foresight, marking the 9th and 10th new products since 2025, with a focus on high-precision measurement and signal integrity analysis [1][2][10]. Product Launch and Market Positioning - The newly launched SDM4075A series 7½-digit digital multimeter achieves extreme measurement accuracy, capturing nV-level voltage and pA-level current, which is crucial for IoT devices and low-power circuits [2][4]. - The SAP8000D active differential probe features an 8 GHz bandwidth and 300 fF ultra-low input capacitance, addressing the challenges of signal integrity in high-speed digital environments [1][6]. Financial Performance and Growth - In the first half of 2025, Dingyang Technology reported a revenue of 279 million yuan, a year-on-year increase of 24.61%, with high-end product lines, particularly high-resolution oscilloscopes and RF microwave products, seeing a revenue growth of 71.92% [7][9]. - The company's net profit attributable to shareholders reached 76.88 million yuan, reflecting a year-on-year growth of 31.54%, indicating an improvement in profitability that outpaces revenue growth [9]. R&D Investment and Innovation - Dingyang Technology has consistently increased its R&D investment, with expenditures rising from 57.61 million yuan in 2022 to 86.10 million yuan in 2023, and projected to exceed 100 million yuan in 2024 [12][14]. - The company’s R&D efforts are aligned with global technological trends, focusing on emerging fields such as 5G communication, new energy vehicles, semiconductors, and artificial intelligence, which are expected to drive growth in the electronic testing and measurement instrument market [12][14]. Strategic Outlook - The launch of SDM4075A and SAP8000D reinforces the company's commitment to innovation as a core growth driver, positioning it well to capitalize on the expanding market opportunities driven by technological advancements and domestic substitution trends [12][14].

Group 1 - The company held its 2025 semi-annual performance briefing on September 17, 2025, via video and online interaction [1][2] - Key executives, including the chairman and general manager, participated in the briefing to discuss the company's operational results, financial status, and development strategies [2] Group 2 - The company plans to maintain stability with core customers while exploring new markets through innovation and product upgrades [3] - There will be a focus on increasing R&D investment in environmentally friendly adhesive materials, leveraging over 20 years of experience in the field [3][4] - The company aims to enhance production efficiency and reduce costs through technology upgrades and process optimization [3] Group 3 - Future R&D efforts will concentrate on electronic adhesives and hot melt adhesives, targeting high-growth markets such as new energy and consumer electronics [5][6] - The company clarified that the high-end environmental wall fabric project is still operational, with no termination, despite a halt in further funding [7] Group 4 - Following the change in the actual controller, the electronic adhesive business is expected to grow, supported by increased demand in domestic new energy and consumer electronics markets [8]

Core Viewpoint - Shanghai Pharmaceuticals' controlling shareholder, Shanghai Industrial Group, plans to increase its stake in the company by acquiring up to 74 million H-shares, signaling confidence in the company's future growth and stability [1][2]. Shareholder Actions - Shanghai Industrial Group's wholly-owned subsidiary, Shanghai International Investment, intends to purchase between 55 million to 74 million H-shares, representing 1.5% to 2% of the company's total share capital [2]. - The initial purchase of 100,000 H-shares was completed on September 15, increasing Shanghai International's holdings to approximately 301 million H-shares, or 8.104% of the total [2][3]. - The acquisition will be conducted through the Hong Kong Stock Exchange without a set price range, using the subsidiary's own funds [2]. Financial Performance - For the first half of 2025, Shanghai Pharmaceuticals reported revenue of 141.6 billion yuan, a year-on-year increase of 1.56%, and a net profit of 4.459 billion yuan, reflecting a significant growth of 51.56% [3]. - The increase in net profit is attributed to the acquisition of a 10% stake in Shanghai Hutchison Pharmaceuticals, which changed the accounting treatment from equity method to consolidation, leading to higher investment income [3]. Research and Development - Shanghai Pharmaceuticals has invested heavily in R&D, with total R&D expenses reaching 76.69 billion yuan from 2022 to the first half of 2025 [1][5]. - The company has 56 new drug pipelines, including 44 innovative drug pipelines, that have received clinical trial approvals [5]. - R&D expenses for the first half of 2025 amounted to 11.48 billion yuan, accounting for 9.44% of the pharmaceutical industrial sales revenue [5]. Market Response - Following the announcement of the share buyback plan, the market showed increased interest in Shanghai Pharmaceuticals, with the A-share price rising to 18.13 yuan and the H-share price to 12.23 HKD [3].

| | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系 | □媒体采访 □业绩说明会 | | 活动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | ☑ | 其他 年安徽上市公司投资者网上集体接待日） （2025 | | 日 期 | 2025 年 9 月 15 日 | | 活动参与人员 | 投资者网上提问 | | 地 点 | "全景路演"网站（ http://rs.p5w.net/） | | 形 式 | 网络远程 | | | 1、董事会秘书唐永亮 | | 接待人 | 2、财务总监吴旭 | | | 3、证券事务代表潘吉沣 | | | 投资者提出的问题及公司回复情况： | | | 1、请问在上海成立公司主要业务是什么？ | | | 回复：上海具有独特的区位优势，公司设立上海子公司致 | | | 力于打造研发创新前沿阵地，市场拓展的重要枢纽，扩张国际 | | | 业务的窗口以及产业投资的关键平台。谢谢！ | | 投资者关系活动 | 2、大股东奥瑞金对所持公司股票有新的信息？ | | 主要内容介绍 | 回复：若有需要披露的信息公司会及时公告。谢谢！ | | | 3、未来有 ...